Peptides, grouped by the effect studied.
Each area groups peptides by the body system and the effects research actually investigates — with evidence level and regulatory status for each entry.
Metabolism
Incretin-based peptides act on the regulation of blood sugar, insulin secretion and satiety. Controlled clinical studies have described effects on fasting glucose, HbA1c and body weight; the predominantly gastrointestinal side-effect profile is comparatively well documented.
One of the best-studied groups. The approved substances are prescription-only; status and indication differ by country.
Recovery
Substances in this group have been investigated mainly in animal models for tissue-regenerating, wound-healing or inflammation-modulating properties. Controlled human studies are lacking for most of them.
Mostly not approved; several are on the WADA list. The evidence is predominantly preclinical.
Cognition
Peptides acting on CNS transmitter systems, neurotrophic factors or social behaviour. The evidence ranges from early clinical studies (e.g. oxytocin) to predominantly preclinical research.
Mixed: some substances are approved medicines, others purely experimental. Western GCP studies are lacking for many.
Growth
GH secretagogues and related peptides studied in the context of growth-hormone release, body composition and ageing. The evidence ranges from early clinical studies to preclinical.
Mostly not approved; many are WADA-listed and may fall under anti-doping law.
This site is intended solely for factual, scientifically oriented information about peptides. It does not constitute medical advice, does not replace a consultation with a doctor and contains no recommendations for use in humans. Peptica sells no substances and names no sources for unapproved substances.